Dental composition and use

• US 10,973,794 B2
• Filed: 02/10/2016
• Issued: 04/13/2021
• Est. Priority Date: 02/11/2015
• Status: Active Grant

• Current Assignee: Calscience International Ltd
• Original Assignee: Calscience Internationalltd
• Inventors: Forbes, Iain William George, Forbes, William
• Primary Examiner(s): Hui, San Ming R
• Application Number:
  US15/550,388
• Publication Number:
  US 20180028481A1
• Time in Patent Office: 1,889 Days
• CPC Class Codes: A61K 2800/782 Enzyme inhibitors; Enzyme antagonists
• CPC Class Codes: A61K 31/216 of acids having aromatic rings, e.g. benactizyne, clofibrate
• CPC Class Codes: A61K 8/37 Esters of carboxylic acids
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61Q 11/00 Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Abstract

Use of a composition for the prevention, amelioration and/or treatment of conditions, disorders and/or diseases associated with senescence and/or inflammation of the teeth and/or associated structures and tissues in the mouth, the composition comprising a conjugate of quinic acid with at least one molecule of caffeic acid, or a derivative, isomer or salt thereof.

Claims

1. A method for the amelioration or treatment of conditions, disorders or diseases associated with senescence of the teeth, associated structures or tissues in the mouth;

or inflammation of the teeth, associated structures or tissues in the mouth, the method comprising administering a composition comprising a conjugate of (a) quinic acid with (b) at least one molecule of caffeic acid, or a derivative, isomer or salt thereof.

2. The method of claim 1, wherein the composition comprises an ester of caffeic acid and quinic acid, a dicaffeoylquinic acid, or a tricaffeoylquinic acid, or a derivative, isomer or salt thereof.

3. The method of claim 1, wherein the composition comprises 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5- dicaffeoylquinic acid, or 3,4,5-tricaffeoylquinic acid, or a derivative, isomer or salt thereof.

4. The method of claim 1, wherein the composition inhibits one or more of a matrix metalloproteinase (MMP), MMP-9, MMP-2, nuclear factor kappa B, a cytokine, or a tissue inhibitor of matrix metalloproteinase (TIMP) activator.

5. The method of claim 1, wherein the method results in (a) an increase in the expression of one or more matrix metalloproteinase (MMP) genes or proteins and (b) the control of the concentration of MMPs in saliva to increase the extracellular matrix cohesion of the teeth and associated structures and tissues of the mouth.

6. The method of claim 1, wherein the composition (a) activates the expression of the sirtuin 3 gene to enhance the production of the sirtuin 3 protein, (b) inhibits the expression of the sirtuin 2 gene, (c) inhibits the production of the sirtuin 2 protein, or (d) a combination thereof.

7. The method of claim 1, wherein the method comprises (a) amelioration or treatment of demineralization of the enamel or dentine of the teeth and associated structures in the mouth and (b) stimulation or promotion of remineralization of teeth or associated structures in the mouth.

8. The method of claim 1, wherein the method comprises stimulation or promotion of remineralization of teeth or associated structures in the mouth following demineralization of teeth.

9. The method of claim 1, wherein the method comprises the amelioration or treatment of leukoplakia.

10. The method of claim 1, wherein the method comprises the amelioration or treatment of chronic inflammatory disease of the teeth and associated structures of the mouth or dental caries.

11. The method of claim 1, wherein the method comprises the amelioration or treatment of conditions of the teeth or associated structures in the mouth associated with senescence.

12. The method of claim 1, wherein the method comprises the amelioration or treatment of tissue shrinkage or contraction which may occur in senescence following application of a dental implant or prosthesis in the mouth.

13. The method of claim 1, wherein the composition is incorporated into a coating or other material used in a dental implant or prosthesis.

14. The method of claim 1, wherein the composition is incorporated into teeth whitening agents and the method comprises the amelioration or treatment of conditions affected by free radicals, hydrogen peroxide or associated derivatives which may be generated by the use of teeth whitening agents.

15. The method of claim 1, wherein the conjugate is extracted from a natural source, is a plant extract, is an artichoke extract, is synthesized, or is engineered from plants, bacteria, fungi, mold, algae or another suitable source.

16. The method of claim 1, wherein the composition comprises at least one acceptable carrier and the conjugate is carried within dental inserts, vesicles, micelles, liposomes, nanoparticles, or other suitable vehicles.

17. The method of claim 1, wherein the composition is directly applied to the teeth or associated structures in the mouth.

18. The method of claim 1, wherein the composition is directly applied to the teeth or associated structures in the mouth by a dental practitioner during a surgical procedure, or by injection, or wherein the composition is applied in the form of a mouthwash, paste, toothpaste, lotion, gel, powder or other suitable medium.

19. The method of claim 1, wherein the composition comprises a free base form of the conjugate or a pharmaceutically acceptable salt of the conjugate.

20. The method of claim 1, wherein the composition is used in combination with one or more other therapies comprising antibodies, analgesics, substances used to neutralize the acidity of saliva, chemotherapy, synergistic compounds, genes, gene products, cell therapy, radiation, or other suitable therapies.